{
    "title": "Apax mulls sale of Neuraxpharm to lock in pharma sector premium -sources",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8506625/Apax-mulls-sale-Neuraxpharm-lock-pharma-sector-premium-sources.html",
    "date": "2020-07-09",
    "keywords": [
        "apax",
        "neuraxpharm",
        "equity",
        "schuetze",
        "group",
        "healthcare",
        "coronavirus",
        "interest",
        "maker",
        "time",
        "investment",
        "sale",
        "pharma",
        "sector",
        "matter",
        "system",
        "auction",
        "cannabis",
        "autumn",
        "process",
        "bank",
        "exit",
        "rothschild",
        "deal",
        "mampa",
        "activity",
        "level",
        "decade",
        "quarter",
        "expansion",
        "balance",
        "wake",
        "outbreak",
        "impact",
        "banker",
        "financing",
        "precrisis",
        "debt",
        "tax",
        "depreciation",
        "amortisation",
        "year",
        "advent",
        "capital",
        "bridgepoint",
        "eqt",
        "cinven",
        "bain",
        "farma",
        "company",
        "health",
        "farmax",
        "credit",
        "agency",
        "moodys",
        "january",
        "dividend",
        "leverage",
        "profitability",
        "ebitda",
        "margin",
        "editing",
        "jane",
        "merriman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}